vs

Side-by-side financial comparison of Strive, Inc. (ASST) and PULSE BIOSCIENCES, INC. (PLSE). Click either name above to swap in a different company.

PULSE BIOSCIENCES, INC. is the larger business by last-quarter revenue ($264.0K vs $255.0K, roughly 1.0× Strive, Inc.). PULSE BIOSCIENCES, INC. runs the higher net margin — -6603.4% vs -75406.7%, a 68803.3% gap on every dollar of revenue.

Strive Asset Management is an American investment management firm founded in 2022. The firm operates mutual funds, exchange-traded products (ETPs), and wealth management services. Headquartered in Columbus, Ohio, it operates as a subsidiary of Strive Enterprises, Inc. and is registered with the U.S. Securities and Exchange Commission (SEC) as an investment adviser.

Colossal Biosciences Inc. is an American biotechnology and genetic engineering company working to de-extinct several extinct animals, including the woolly mammoth, the Tasmanian tiger, the northern white rhinoceros, the dire wolf, the dodo, and the moa. In 2023, it stated that it wants to have woolly mammoth hybrid calves by 2028, and wants to reintroduce them to the Arctic tundra habitat. Likewise, it launched the Tasmanian Thylacine Advisory Committee, a thylacine research project to releas...

ASST vs PLSE — Head-to-Head

Bigger by revenue
PLSE
PLSE
1.0× larger
PLSE
$264.0K
$255.0K
ASST
Higher net margin
PLSE
PLSE
68803.3% more per $
PLSE
-6603.4%
-75406.7%
ASST

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASST
ASST
PLSE
PLSE
Revenue
$255.0K
$264.0K
Net Profit
$-192.3M
$-17.4M
Gross Margin
Operating Margin
-17288.6%
-6914.0%
Net Margin
-75406.7%
-6603.4%
Revenue YoY
-74.1%
Net Profit YoY
-2726.9%
10.1%
EPS (diluted)
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASST
ASST
PLSE
PLSE
Q4 25
$264.0K
Q3 25
$255.0K
$86.0K
Q2 25
$173.3K
$0
Q1 25
$170.7K
$0
Q4 24
$212.8K
$0
Q3 24
$984.0K
$0
Q2 24
$93.0K
$0
Q1 24
$124.8K
$0
Net Profit
ASST
ASST
PLSE
PLSE
Q4 25
$-17.4M
Q3 25
$-192.3M
$-19.4M
Q2 25
$-8.9M
$-19.2M
Q1 25
$-3.7M
$-16.8M
Q4 24
$-4.1M
$-19.4M
Q3 24
$-6.8M
$-12.7M
Q2 24
$-5.9M
$-11.4M
Q1 24
$-4.8M
$-10.1M
Gross Margin
ASST
ASST
PLSE
PLSE
Q4 25
Q3 25
-224.4%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ASST
ASST
PLSE
PLSE
Q4 25
-6914.0%
Q3 25
-17288.6%
-23682.6%
Q2 25
-1553.9%
Q1 25
-970.5%
Q4 24
-5889.5%
Q3 24
-712.4%
Q2 24
-1857.2%
Q1 24
-1110.9%
Net Margin
ASST
ASST
PLSE
PLSE
Q4 25
-6603.4%
Q3 25
-75406.7%
-22540.7%
Q2 25
-5122.4%
Q1 25
-2195.6%
Q4 24
-1935.5%
Q3 24
-691.3%
Q2 24
-6313.1%
Q1 24
-3837.7%
EPS (diluted)
ASST
ASST
PLSE
PLSE
Q4 25
Q3 25
$-0.22
Q2 25
$-0.17
Q1 25
$-0.13
Q4 24
$-5.62
Q3 24
$-3.06
Q2 24
$-0.58
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASST
ASST
PLSE
PLSE
Cash + ST InvestmentsLiquidity on hand
$109.1M
$80.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.4M
$80.7M
Total Assets
$792.6M
$94.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASST
ASST
PLSE
PLSE
Q4 25
$80.7M
Q3 25
$109.1M
$95.2M
Q2 25
$2.5M
$106.3M
Q1 25
$4.2M
$119.3M
Q4 24
$6.2M
$118.0M
Q3 24
$2.1M
$79.0M
Q2 24
$1.9M
$26.2M
Q1 24
$1.9M
$34.9M
Stockholders' Equity
ASST
ASST
PLSE
PLSE
Q4 25
$80.7M
Q3 25
$779.4M
$92.7M
Q2 25
$10.7M
$104.5M
Q1 25
$19.6M
$118.5M
Q4 24
$23.3M
$114.9M
Q3 24
$27.5M
$79.1M
Q2 24
$5.4M
$27.0M
Q1 24
$11.3M
$36.3M
Total Assets
ASST
ASST
PLSE
PLSE
Q4 25
$94.5M
Q3 25
$792.6M
$108.8M
Q2 25
$3.3M
$120.3M
Q1 25
$5.0M
$133.4M
Q4 24
$28.2M
$132.5M
Q3 24
$2.6M
$93.0M
Q2 24
$2.4M
$40.4M
Q1 24
$2.1M
$49.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASST
ASST
PLSE
PLSE
Operating Cash FlowLast quarter
$-14.0M
$-14.8M
Free Cash FlowOCF − Capex
$-14.9M
FCF MarginFCF / Revenue
-5628.8%
Capex IntensityCapex / Revenue
0.0%
39.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-54.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASST
ASST
PLSE
PLSE
Q4 25
$-14.8M
Q3 25
$-14.0M
$-13.0M
Q2 25
$-1.7M
$-12.8M
Q1 25
$-1.6M
$-13.5M
Q4 24
$-21.6M
$-9.1M
Q3 24
$-13.2M
$-9.0M
Q2 24
$-1.3M
$-8.4M
Q1 24
$-1.0M
$-9.8M
Free Cash Flow
ASST
ASST
PLSE
PLSE
Q4 25
$-14.9M
Q3 25
$-13.1M
Q2 25
$-12.9M
Q1 25
$-13.6M
Q4 24
$-21.6M
$-9.2M
Q3 24
$-13.4M
$-9.1M
Q2 24
$-1.3M
$-8.4M
Q1 24
$-1.1M
$-9.8M
FCF Margin
ASST
ASST
PLSE
PLSE
Q4 25
-5628.8%
Q3 25
-15233.7%
Q2 25
Q1 25
Q4 24
-10161.2%
Q3 24
-1360.3%
Q2 24
-1379.4%
Q1 24
-844.7%
Capex Intensity
ASST
ASST
PLSE
PLSE
Q4 25
39.8%
Q3 25
0.0%
72.1%
Q2 25
Q1 25
Q4 24
11.3%
Q3 24
18.8%
Q2 24
3.1%
Q1 24
9.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons